Acquisition Archives - HealthQuill

AbbVie Inc. will acquire Aliada Therapeutics, a biotechnology company focused on developing drugs to treat diseases of the central nervous system such as Alzheimer’s disease, for $1.4 billion in cash.

AbbVie to acquire Aliada for $1.4 billion, bags Alzheimer’s therapy

AbbVie Inc. will acquire Aliada Therapeutics, a biotechnology company focused on developing drugs to treat diseases of the central nervous system such as.

by HealthQuill
October 28, 2024
0 Comments

Modifi Biosciences, Inc., a Yale University spinout company formed in 2021, has been acquired by Merck & Co. for about $1.3 billion to gain access to therapies that aim to kill cancer cells by modifying cancer DNA selectively.

Drugs Health Pharma

Merck acquires Yale University spinout Modifi Biosciences for up to $1.3 billion

Modifi Biosciences, Inc., a Yale University spinout company formed in 2021, has been acquired by Merck & Co. for about $1.3 billion to.

by HealthQuill
October 24, 2024
0 Comments

H. Lundbeck A/S, a Danish drugmaker, plans to acquire California, US-based Longboard Pharmaceuticals for $2.6 billion, giving it access to a late-stage drug to treat seizures in a group of rare epilepsies.

Drugs Health Pharma

Lundbeck targets epileptic drug, to buy Longboard for $2.6 billion

H. Lundbeck A/S, a Danish drugmaker, plans to acquire California, US-based Longboard Pharmaceuticals for $2.6 billion, giving it access to a late-stage drug.

by HealthQuill
October 14, 2024
0 Comments

The Abu Dhabi National Oil Company, ADNOC, the state-owned oil company of the United Arab Emirates, will buy Germany’s chemicals maker Covestro AG for 11.7 billion euros ($13 billion).

Climate Health Pharma

ADNOC to buy Germany’s chemical producer Covestro for $13 billion

The Abu Dhabi National Oil Company, ADNOC, the state-owned oil company of the United Arab Emirates, will buy Germany’s chemicals maker Covestro AG.

by HealthQuill
October 1, 2024
0 Comments

Genentech, a member of the Roche Group, will acquire a portfolio of CDK inhibitors to treat breast cancer from Regor Pharmaceuticals for an upfront payment of $850 million.

Drugs Health Pharma

Roche arm to buy breast cancer portfolio from Regor for $850 million

Genentech, a member of the Roche Group, will acquire a portfolio of CDK inhibitors to treat breast cancer from Regor Pharmaceuticals for an.

by HealthQuill
September 30, 2024
0 Comments

US-based pharmaceutical company Organon & Co., will acquire Riovant Sciences Ltd’s arm — Dermavant Sciences Ltd., specialising in immuno-dermatology — for $1.2 billion.

Drugs Health Pharma

Organon & Co to buy Riovant’s arm Dermavant Sciences for $1.2 billion

US-based pharmaceutical company Organon & Co., will acquire Riovant Sciences Ltd’s arm — Dermavant Sciences Ltd., specialising in immuno-dermatology — for $1.2 billion.

by HealthQuill
September 18, 2024
0 Comments

EQT Private Capital Asia will acquire a controlling stake in GeBBS Healthcare Solutions, a provider of healthcare outsourcing solutions from ChrysCapital, according to a statement from EQT.

Drugs Health Pharma

EQT Private Capital Asia to acquire controlling stake in US-based GeBBS

EQT Private Capital Asia will acquire a controlling stake in GeBBS Healthcare Solutions, a provider of healthcare outsourcing solutions from ChrysCapital, according to.

by HealthQuill
September 9, 2024
0 Comments

McKesson Corporation, the ninth-largest company by revenue in the US, will acquire Community Oncology Revitalization Enterprise Ventures, for $2.4 billion in cash to expand its oncology portfolio.

Drugs Health Pharma

McKesson Corp., to acquire Core Ventures for $2.4 billion in cash

McKesson Corporation, the ninth-largest company by revenue in the US, will acquire Community Oncology Revitalization Enterprise Ventures, for $2.4 billion in cash to expand its.